Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | STARPHARMA HOLDINGS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
17.04. | STARPHARMA HOLDINGS LIMITED: Change in Director's Interest Notice - R Thomas | - | ASX | ||
16.04. | STARPHARMA HOLDINGS LIMITED: Change in Director's Interest Notice - R Basser | 1 | ASX | ||
15.04. | STARPHARMA HOLDINGS LIMITED: Change in Director's Interest Notice - R Thomas | 2 | ASX | ||
08.04. | Medicxi and Starpharma to develop dendrimer-based cancer treatments | 4 | Pharmaceutical Technology | ||
08.04. | Starpharma and Medicxi partner to create UK-based oncology company called Petalion Therapeutics | 2 | smallcaps.com.au | ||
08.04. | STARPHARMA HOLDINGS LIMITED: Investor Webinar Notification SPL Medicxi Partnership | 1 | ASX | ||
08.04. | STARPHARMA HOLDINGS LIMITED: Starpharma and Medicxi Partnership Petalion Therapeutics | 1 | ASX | ||
01.03. | STARPHARMA HOLDINGS LIMITED: S&P DJI Announces March 2024 Quarterly Rebalance | - | ASX | ||
26.02. | STARPHARMA HOLDINGS LIMITED: Half Yearly Report and Accounts | - | ASX | ||
19.02. | Starpharma's VivaGel Approval Denied By FDA | 4 | RTTNews | ||
19.02. | ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc | 2 | Stockhead | ||
19.02. | Starpharma Holdings slumps on FDA denial for therapy product | 3 | Reuters | ||
18.02. | STARPHARMA HOLDINGS LIMITED: VivaGel BV US FDA Appeal Outcome | - | ASX | ||
06.02. | STARPHARMA HOLDINGS LIMITED: Application for quotation of securities - SPL | 3 | ASX | ||
29.01. | STARPHARMA HOLDINGS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
28.01. | STARPHARMA HOLDINGS LIMITED: Viraleze shows antiviral efficacy in COVID-19 patients | 1 | ASX | ||
22.01. | STARPHARMA HOLDINGS LIMITED: VivaGel BV sales and distribution agreement MENA region | 1 | ASX | ||
19.01. | STARPHARMA HOLDINGS LIMITED: DEP cabazitaxel data presentation at ASCO GI cancer meeting | 1 | ASX | ||
12.01. | STARPHARMA HOLDINGS LIMITED: Notification of cessation of securities - SPL | 2 | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 45,110 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
KYMERA THERAPEUTICS | 37,400 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 8,000 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
DYNE THERAPEUTICS | 26,080 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,840 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
NUVALENT | 70,35 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
CG ONCOLOGY | 36,270 | 0,00 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
JANUX THERAPEUTICS | 64,78 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
ANNEXON | 4,880 | 0,00 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
SANA BIOTECHNOLOGY | 10,440 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
CABALETTA BIO | 12,390 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 27,270 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 26,450 | 0,00 % | Navigating 7 Analyst Ratings For Avidity Biosciences | ||
HARMONY BIOSCIENCES | 31,570 | 0,00 % | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
ADMA BIOLOGICS | 6,810 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024 |